You are here: Industry Insights > Biohaven

News List

Biohaven Wins FDA Approval for NURTEC ODT contractpharma
March 18, 2020
Developed in partnership with Catalent using its Zydis orally disintegrating tablet (ODT) technology.
Biohaven drug wins US FDA approval for use in relieving migraine headaches expresspharma
March 03, 2020
A single oral dose of the 75 mg tablet can provide fast pain relief, return patients to normal function within an hour, and remain effective for up to 48 hours for many patients, the company said.
Biohaven Achieves Positive Topline Results in Migraine Study americanpharmaceuticalreview
December 18, 2019
Biohaven Pharmaceutical announced positive topline results from its randomized, dose ranging, placebo controlled, pivotal Phase 2/3 clinical trial evaluating the efficacy and tolerability ...
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the USPTO americanpharmaceuticalreview
December 11, 2019
Biohaven Pharmaceutical announced the U.S. Patent and Trademark Office (USPTO) issued U.S. Pat. No. 10,485,791 on November 26, 2019 relating to troriluzole.
Biohaven Completes Enrollment in Phase 3 Migraine Prevention Trial americanpharmaceuticalreview
August 09, 2019
Biohaven has reported completion of enrollment in its pivotal Phase 3 preventive treatment of migraine trial with rimegepant, its lead oral calcitonin gene-related peptide (CGRP) receptor antagonist product candidate.
Biohaven Enrolls First Patient in Verdiperstat Phase 3 Clinical Trial americanpharmaceuticalreview
August 01, 2019
Biohaven announced it has enrolled the first patient in a Phase 3 clinical trial to evaluate the efficacy and safety of verdiperstat in subjects with Multiple System Atrophy (MSA).
Biohaven’s Nurtec fails to obtain FDA approval for ALS pharmaceutical-technology
July 23, 2019
Biohaven Pharmaceutical has failed to receive the US Food and Drug Administration (FDA) approval for Nurtec (riluzole).
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A fiercepharma
July 13, 2019
Aiming to break into a three-way battle among large drugmakers in the brand-new CGRP migraine class, tiny Biohaven Pharmaceutical has released detailed data for its own candidate, which one group of analysts figures could reach blockbuster status.
Biohaven Enrolls First Patient in Rimegepant Phase 2 Clinical Trial americanpharmaceuticalreview
July 03, 2019
Biohaven announced that the first patient has been enrolled in a Phase 2 clinical trial assessing the efficacy and safety of rimegepant in treatment refractory trigeminal neuralgia.
Migraine drug developer Biohaven considering potential sale firstwordpharma
April 14, 2019
According to people familiar with the matter, Biohaven Pharmaceutical is examining its options……

Previous page 1 2 3 4 Next page